Compare ESP & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | TARA |
|---|---|---|
| Founded | 1928 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 159.6M |
| IPO Year | 1995 | 2014 |
| Metric | ESP | TARA |
|---|---|---|
| Price | $54.06 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 25.7K | ★ 1.3M |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | 28.81 | ★ 38.25 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $46,124,325.00 | $2,948,000.00 |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $14.26 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.82 | $2.28 |
| 52 Week High | $74.77 | $7.82 |
| Indicator | ESP | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 38.18 |
| Support Level | $49.40 | $2.28 |
| Resistance Level | $61.35 | $2.83 |
| Average True Range (ATR) | 1.94 | 0.16 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 41.56 | 35.45 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.